Kiniksa Pharmaceuticals International, plc Debt Securities, Available-for-sale, Unrealized Loss
Kiniksa Pharmaceuticals International, plc (KNSA) reported Debt Securities, Available-for-sale, Unrealized Loss of $9.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-04-25.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss · last filed 2024-04-25
- Kiniksa Pharmaceuticals International, plc debt securities, available-for-sale, unrealized loss for the quarter ending 2024-03-31 was $9.00K, a 800.00% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc debt securities, available-for-sale, unrealized loss for the quarter ending 2023-09-30 was -$13.00K.
- Kiniksa Pharmaceuticals International, plc debt securities, available-for-sale, unrealized loss for the quarter ending 2023-06-30 was $14.00K.
- Kiniksa Pharmaceuticals International, plc debt securities, available-for-sale, unrealized loss for the quarter ending 2023-03-31 was $1.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss 3 month | Debt Securities, Available-for-sale, Unrealized Loss 6 month | Debt Securities, Available-for-sale, Unrealized Loss 9 month | Debt Securities, Available-for-sale, Unrealized Loss 12 month |
|---|---|---|---|---|
| 2024-03-31 | $9.00K 10-Q · filed 2024-04-25 | |||
| 2023-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.00K derived: sum of 2 quarters · filed 2023-11-02 | $2.00K 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $15.00K 10-Q · filed 2023-08-01 | ||
| 2023-03-31 | $1.00K 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | $4.00K 10-Q · filed 2023-11-02 |